T1D Fund

The #T1DFund team is looking forward to attending #ada2024 – we're very excited to hear about all the latest scientific advances in #t1d as well as hear from many experts in the field. Be sure to check out the #scientificsessions where some of our portfolio companies like SAB BIO will be presentation. We can't wait to see everyone there!

We're proud to support Cour Pharmaceuticals Development Co., Inc. and their groundbreaking work in treating type 1 diabetes. In a recent Q&A with Drug Target Review, CEO John J. Puisis delves into the innovative nanoparticle platform behind their preclinical T1D program, CNP-103. This cutting-edge technology is showing promise in addressing the immune-mediated destruction of pancreatic islet cells, offering hope for halting disease progression in T1D. Exciting advancements like these exemplify the potential of our investments to transform lives. #T1DResearch #InnovativeHealthcare #T1D

We're thrilled to be a part of the exciting brand update and share that JDRF International is now Breakthrough T1D! This change underscores the organization’s commitment to accelerating life-changing breakthroughs to cure, prevent, and treat type 1 diabetes (T1D) and its complications. As the T1D Fund, our mission remains steadfast to drive cures for T1D by investing alongside the innovators in life sciences. We continue to support companies that play a role in the discovery and therapeutic development of effective solutions to T1D.

We are happy to announce Sean O'Connor's promotion to Principal at the T1D Fund.     Sean has been an integral part of our investment team since joining in December 2022. We look forward to continuing to leverage his expertise and skill set as we pursue our mission of accelerating curative therapies for T1D.    #T1DCures #promotion #employeespotlight  

Congratulations to the SAb Biotherapeutics team for achieving FDA clearance for SAB-142's IND. We are proud to support your efforts towards the clinic which has great potential for the type one diabetes community. The program is promising as a disease modifying therapy for T1D. #t1d

We are excited to welcome Eric Shen to the JDRF T1D Fund as our Chief of Staff.   Eric brings a wealth of experience from his previous roles in corporate development, strategy, and operations across the biotech ecosystem. He joins our leadership team to help formulate and execute on various strategic initiatives to accomplish the mission of accelerating life-changing solutions to prevent, treat, and ultimately cure #T1D.

Join our Managing Director Katie Ellias on May 10 at 1:45pm ET at the 2024 Convergence Forum for a panel discussion on the funding strategy of foundations. The annual gathering brings together high-level healthcare leaders to discuss and debate the most pressing topics of interest to the industry. To learn more, visit: https://lnkd.in/ejeUvSBb   #2024convergenceforum #employeespotlight #healthcareinnovaton

We are excited to welcome Sylvia Tobé to the T1D Fund leadership team. Sylvia brings a decade of life sciences industry experience along with significant expertise in the autoimmune disease arena. She will work closely alongside our other Managing Directors and other members of the investment team to advance our mission to accelerate the progress of life changing #T1D therapies and treatments. https://lnkd.in/gv8WyzxB

JDRF T1D Fund is proud to be an investor and supporter of vTv Therapeutics LLC continued study of cadisegliatin as a potential adjunctive therapy to insulin. We look forward to collaborating with Paul Sekhri and his talented team as they continue to thoughtfully advance this highly promising program. Our colleagues at JDRF International have been involved with vTv for many years, and it is great to now bring the T1D Fund into the mix.

We’re proud to announce our participation alongside healthcare-focused institutional investors including Samsara BioCapital in vTv Therapeutics LLC's $51 million private placement to fully fund the first Phase 3 study of cadisegliatin, an adjunctive therapy to insulin for the treatment of type 1 diabetes, slated to kick off in mid-2024. The investment underscores our commitment to backing innovative companies focused on developing potentially game-changing solutions for the T1D community worldwide. #insulin #t1d #healthcare #investment